{"schema_version":"secwatch.filing_event.v1","accession":"0001658247-26-000011","form_type":"8-K","ticker":"CRNX","cik":"0001658247","company_name":"Crinetics Pharmaceuticals, Inc.","filed_at":"2026-02-26T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.787838+00:00","generated_at":"2026-05-15T23:39:47.202875+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Crinetics Q4 2025: Palsonify launch revenue $5.4M, net loss $122.8M; EU CHMP positive opinion","bullets":["PALSONIFY net product revenue $5.4M in Q4 2025; >200 enrollment forms by Dec end; 125+ HCPs prescribed in Q4.","CHMP adopted positive opinion recommending EU marketing authorization for paltusotine in acromegaly; EC decision pending.","Seamless Phase 2/3 EQUILIBRIUM study of atumelnant in Cushing's syndrome to start H1 2026; Phase 3 trials for CAH and carcinoid syndrome initiated.","Full-year 2025 net loss $465.3M; cash used $326.2M, below guidance; cash $1.0B at Dec 31, 2025 (pro forma $1.4B post Jan 2026 offering).","2026 GAAP OpEx guidance $600-650M; non-GAAP OpEx $480-520M; R&D and SG&A investments continue."],"urls":{"canonical":"https://secwatch.observer/filing/0001658247-26-000011","json":"https://secwatch.observer/filing/0001658247-26-000011.json","markdown":"https://secwatch.observer/filing/0001658247-26-000011.md","text":"https://secwatch.observer/filing/0001658247-26-000011.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1658247/000165824726000011/0001658247-26-000011-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1658247/000165824726000011/crnx-20260226.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T23:39:47.202875+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}